• Molecule’s (MLCL) newest beverage brand “Phresh,” picked up by the Ontario Cannabis Store
  • Phresh is the sixth brand accepted and sold by the OCS on behalf of Canadian licensed cannabis beverage production company, Molecule
  • Molecule works with client-partners to engage in the production of cannabis-infused beverages and edibles
  • One of Molecule’s goals is to be the on-ramp for companies wishing to enter the cannabis beverage and edibles market
  • Molecule Holdings Inc. (MLCL) is up 4.35 per cent and is trading at C$0.12 at 11:41 pm ET.

Molecule Holdings Inc. (MLCL), its newest brand Phresh has been picked up by the Ontario Cannabis Store for online and retail distribution.

Phresh is the sixth brand accepted and sold by the OCS on behalf of Canadian licensed cannabis beverage production company, Molecule. Phresh Strawberry Kiwi is anticipated to launch in time for the busy summer season.

“We are especially excited about the Phresh brand being picked up so quickly. The product pushes the boundaries on several fronts and represents the single largest order we have received as a company to date,” said President and CEO Phil Waddington.

Molecule works with client-partners to engage in the production of cannabis-infused beverages and edibles.

It provides the infrastructure, know-how, technology, and licensing for craft producers to create consumable cannabis products.

One of Molecule’s goals is to be the on-ramp for companies wishing to enter the cannabis beverage and edibles market, but who choose not to go through the significant process of obtaining the required cannabis licences.

Molecule Holdings Inc. (MLCL) is up 4.35 per cent and is trading at C$0.12 at 11:41 pm ET.

More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.